Immunic, Inc. (IMUX)
IMUXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$8.04
+0.1200 (+1.52%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $109.70m
- P/E
- –
- EPS, last 4 quarters
- $-4.38
- Dividend yield
- –
- Day range
- –
- 52-week range
- $5.06 to $17.43
- Average volume
- 375.0k
- Previous close
- $7.92
Analysts
10 coveringStrong Buy10 buy, 0 hold, 0 sell
Targets a year out average $36.56, +354.7% from here
Earnings
next estimate $-0.8200Next report Nov 12, 2026
Sep 2025
+27.8%
Dec 2025
-20.0%
Mar 2026
-52.1%
Jun 2026
+35.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$25.99m | -$23.33m | -$33.23m | -$35.33m |
| Net income | -$25.58m | -$19.30m | -$32.59m | -$34.10m |
News
8 latest- Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 ResultsMarketBeat · 5 days ago
- Immunic, Inc. Hosts Progressive Multiple Sclerosis Research and Development Day Webinar on November 5, 2026Fintel · 5 days ago
- New Strong Buy Stocks for October 22ndZacks · Oct 22, 2026
- Immunic Names Jaa Roberson Chief People Officer RTTNews · Oct 19, 2026
- Immunic Posts Wider Q2 Loss; Expects Twin Phase 3 Results For Multiple Sclerosis By Year-End 2026 RTTNews · Aug 13, 2026
- Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?Zacks · Aug 13, 2026
- Immunic Names Erik Lundgren Chief Executive Officer RTTNews · May 27, 2026
- Immunic Appoints Michael Panzara As CMO RTTNews · Apr 28, 2026
The company
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is expected later in 2026. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- imux.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.